
    
      A screening period, up to 3 weeks, applied only for participants who came from DRI12544
      study. The total study duration, per participant, was a maximum of 108 weeks (or 111 weeks
      considering a maximum screening period of 3 weeks for study DRI12544) for the participants
      enrolled prior to Amendment 04 approval and a maximum of 60 weeks for the participants
      enrolled after Amendment 04 approval.

      Following amendment 04 (dated 31 Oct 2016) the open-label treatment duration was amended to
      48 weeks (1 year); and the 16-week post-treatment period was shortened to 12 weeks.
    
  